683 related articles for article (PubMed ID: 27028913)
1. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
2. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
3. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.
Murphy SM; Polsky D; Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Bonnie RJ; Gordon M; Chen DT; Boney TY; O'Brien CP
Addiction; 2017 Aug; 112(8):1440-1450. PubMed ID: 28239984
[TBL] [Abstract][Full Text] [Related]
6. Extended-release naltrexone opioid treatment at jail reentry (XOR).
McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
[TBL] [Abstract][Full Text] [Related]
7. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
8. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
9. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
Bahji A; Carlone D; Altomare J
Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
[TBL] [Abstract][Full Text] [Related]
10. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
11. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J
Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
13. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
[TBL] [Abstract][Full Text] [Related]
14. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of oral naltrexone for treating opioid-dependent offenders.
Coviello DM; Cornish JW; Lynch KG; Alterman AI; O'Brien CP
Am J Addict; 2010; 19(5):422-32. PubMed ID: 20716305
[TBL] [Abstract][Full Text] [Related]
16. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
17. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
Springer SA; Brown SE; Di Paola A; Altice FL
Drug Alcohol Depend; 2015 Dec; 157():158-65. PubMed ID: 26560326
[TBL] [Abstract][Full Text] [Related]
18. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
19. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
